Search results for "combination"

showing 10 items of 1379 documents

A critical evaluation of caplacizumab for the treatment of acquired thrombotic thrombocytopenic purpura

2020

Introduction: Acquired thrombotic thrombocytopenic purpura (aTTP) is a thrombotic microangiopathy caused by inhibitory autoantibodies against ADAMTS13 protein. Until recently, the combination of plasma exchange (PEX) and immunosuppression has been the standard front-line treatment in this disorder. However, aTTP-related mortality, refractoriness, and relapse are still a matter of concern. Areas covered: The better understanding of the pathophysiological mechanisms of aTTP has allowed substantial improvements in the diagnosis and treatment of this disease. Recently, the novel anti-VWF nanobody caplacizumab has been approved for acute episodes of aTTP. Caplacizumab is capable to block the adh…

Thrombotic microangiopathyExacerbationvirusesmedicine.medical_treatmentADAMTS13 ProteinDiseaseBioinformaticsAutoantigens03 medical and health sciencesPlatelet Adhesiveness0302 clinical medicineFibrinolytic AgentsProtein DomainsCrotalid Venomsvon Willebrand FactormedicineHumansImmunologic FactorsMulticenter Studies as TopicLectins C-TypeMolecular Targeted TherapyDrug ApprovalClinical Trials as TopicAcquired Thrombotic Thrombocytopenic PurpuraPlasma ExchangePurpura Thrombotic Thrombocytopenicbusiness.industryStandard treatmentfungiImmunosuppressionDrugs InvestigationalHematologyAptamers NucleotideSingle-Domain Antibodiesbiochemical phenomena metabolism and nutritionmedicine.diseaseCombined Modality TherapyRecombinant ProteinsADAMTS13AcetylcysteineTreatment Outcome030220 oncology & carcinogenesisDrug Therapy CombinationCaplacizumabbusinessImmunosuppressive Agents030215 immunologyExpert Review of Hematology
researchProduct

Triiodothyronine alongside levothyroxine in the management of hypothyroidism?

2021

The current guideline-based management of hypothyroidism recommends monotherapy with levothyroxine (LT4), titrated to maintain the level of thyrotropin within a euthyroid reference range. This has been successful for most people with hypothyroidism, but a substantial minority still report symptoms of hypothyroidism unexplained by a comorbid medical condition. LT4 is essentially a prodrug for triiodothyronine (T3), the thyroid hormone that acts on target tissues in the brain and the periphery. Thyroid hormone replacement with LT4 alone does not restore physiological tissue levels of thyroid hormones, particularly T3. During the last two decades, much interest has focussed on the potential of…

Thyroid Hormonesendocrine systemendocrine system diseasesCombination therapyDeiodinaseLevothyroxineThyrotropinBioinformaticsHypothyroidismmedicineHumansEuthyroidTriiodothyroninebiologybusiness.industryThyroidGeneral MedicineThyroxinemedicine.anatomical_structurebiology.proteinTriiodothyronineThyroid functionbusinesshormones hormone substitutes and hormone antagonistsmedicine.drugHormoneCurrent Medical Research and Opinion
researchProduct

Cytotoxicity and bioactivity of various pulpotomy materials on stem cells from human exfoliated primary teeth.

2017

Aims To investigate the cytotoxicity and bioactivity of several pulpotomy materials: Biodentine (Septodont, Saint-Maur-des-Fosses, France) MTA (Angelus, Londrina, PR, Brazil), Theracal LC (Bisco Inc., Schamburg, IL, USA) and IRM (Dentsply DeTrey GmbH, Konstanz, Germany), after contact with stem cells isolated from human exfoliated primary teeth (SHEDs). Methodology SHEDs were cultured in the presence of the eluates of various pulpotomy materials for 24, 48 and 72 h. Cell viability was determined by mitochondrial dehydrogenase enzymatic (MTT) assay. Apoptosis and changes in cell phenotype were evaluated by flow cytometry. Also, an in vitro scratch wound-healing assay was used to determine th…

Time FactorsCell SurvivalPulpotomyDentistryApoptosis02 engineering and technologyMatrix (biology)In Vitro TechniquesCell morphologyFlow cytometry03 medical and health sciences0302 clinical medicineCell MovementMaterials TestingmedicineHumansMethylmethacrylatesViability assayTooth DeciduousZinc Oxide-Eugenol CementCytotoxicityAluminum CompoundsGeneral DentistryCells Culturedmedicine.diagnostic_testChemistrybusiness.industrySilicatesStem CellsOxides030206 dentistryCalcium Compounds021001 nanoscience & nanotechnologyFlow CytometryMolecular biologyStainingDrug CombinationsPhenotypeApoptosisPulpotomyMicroscopy Electron Scanning0210 nano-technologybusinessPulp Capping and Pulpectomy AgentsInternational endodontic journal
researchProduct

Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD

2012

Bronchodilators are central in the symptomatic management of chronic obstructive pulmonary disease (COPD). Long-acting muscarinic antagonists (LAMAs) and long-acting β(2)-agonists (LABAs) are the main classes of long-acting bronchodilators. To date, tiotropium is the only once-daily LAMA available for the treatment of COPD. Glycopyrronium is a novel LAMA, currently in development for COPD. Phase II studies have shown that glycopyrronium 50 μg once daily provides clinically significant 24-hour bronchodilation with a rapid onset of action, which is faster than that of tiotropium, and a favorable safety and tolerability profile. The Phase III GLycopyrronium bromide in COPD airWays (GLOW) progr…

Time FactorsCombination therapymuscarinic antagonistReviewMuscarinic AntagonistsPlaceboNVA237Severity of Illness IndexDrug Administration Schedulechronic obstructive pulmonary diseaseglycopyrroniumPulmonary Disease Chronic ObstructiveAdministration InhalationHumansMedicineGlycopyrronium bromideAdverse effectLungCOPDExercise Tolerancebiologybusiness.industryGeneral MedicineLamamedicine.diseasebiology.organism_classificationonce dailyGlycopyrrolateBronchodilator Agentsrespiratory tract diseasesTreatment OutcomeTolerabilityAnesthesiaIndacaterolbusinessmedicine.drugInternational Journal of Chronic Obstructive Pulmonary Disease
researchProduct

Management of HCV-Related Liver Disease in Hemophilia and Thalassemia

2018

AbstractChronic infection with the hepatitis C virus (HCV) has long been the dominant complication of substitution therapy in patients with inherited blood disorders and the cause of anticipated death due to end-stage liver disease. In hemophilia, transmission of HCV with clotting factors concentrates started to be curbed in the mid-1980s following the adoption of procedures of virus inactivation of concentrates based on heat, whereas in the 1990s treatment of HCV infection with interferon monotherapy was attempted, however, with little success. The advent of combination therapy of interferon with ribavirin led to a substantial improvement of treatment outcome (40% rate of cure), that howev…

Time FactorsTime FactorThalassemiaHepatitis C virusPopulationAdministration Oral030204 cardiovascular system & hematologyHemophilia Amedicine.disease_causeAntiviral Agents03 medical and health scienceschemistry.chemical_compoundLiver disease0302 clinical medicinesickle cell anemiaRisk FactorshemophiliamedicineHumansBlood TransfusioneducationImmunodeficiencyAntiviral AgentClotting factoreducation.field_of_studydirect antiviral agentHepatologybusiness.industryRisk FactorRibavirinHepatitis CHepatitis C Chronicmedicine.diseaseTreatment OutcomechemistryImmunologyThalassemiaDrug Therapy Combination030211 gastroenterology & hepatologyhepatitis CbusinessHumanSeminars in Liver Disease
researchProduct

Boceprevir is highly effective in treatment-experienced hepatitis C virus-positive genotype-1 menopausal women

2014

AIM: To investigate the safety/efficacy of Boceprevirbased triple therapy in hepatitis C virus (HCV)-G1 menopausal women who were historic relapsers, partial-responders and null-responders. METHODS: In this single-assignment, unblinded study, we treated fifty-six menopausal women with HCV-G1, 46% F3-F4, and previous PEG-α/RBV failure (7% null, 41% non-responder, and 52% relapser) with 4 wk lead-in with PEG-IFNα2b/RBV followed by PEGIFNα2b/RBV+Boceprevir for 32 wk, with an additional 12 wk of PEG-IFN-α-2b/RBV if patients were HCV-RNA-positive by week 8. In previous null-responders, 44 wk of triple therapy was used. The primary objective of retreatment was to verify whether a sustained virolo…

Time FactorsViral HepatitisClinical Trials StudyHepacivirusViral hepatitiPolyethylene GlycolPolyethylene Glycolschemistry.chemical_compoundPegylated interferonOdds RatioMultivariate AnalysiPegylated InterferonGastroenterologyGeneral MedicineHepatitis CHepatitis c virus treatmentMiddle AgedRecombinant ProteinViral LoadGenotype 1Recombinant ProteinsMenopauseTreatment OutcomeItalyRNA ViralDrug Therapy CombinationFemaleMenopauseViral hepatitisViral loadPegylated interferonHumanmedicine.drugmedicine.medical_specialtyGenotypeLogistic ModelProlineTime FactorInterferon alpha-2Hepatitis C virus treatmentAntiviral AgentsPharmacotherapyInternal medicineBoceprevirRibavirinmental disordersmedicineHumansAntiviral AgentHepacivirubusiness.industryInterferon-alphaBiomarkerGenotype 1; Hepatitis c virus treatment; Menopause; Pegylated interferon; Viral hepatitis; Antiviral Agents; Biomarkers; Drug Therapy Combination; Female; Genotype; Hepacivirus; Hepatitis C Chronic; Humans; Interferon-alpha; Italy; Logistic Models; Middle Aged; Multivariate Analysis; Odds Ratio; Polyethylene Glycols; Proline; RNA Viral; Recombinant Proteins; Ribavirin; Time Factors; Treatment Outcome; Viral Load; Menopause; GastroenterologyHepatitis C Chronicmedicine.diseaseVirologyLogistic ModelschemistryHepatitis C Virus PositiveMultivariate AnalysisGenotype 1; Hepatitis C virus treatment; Menopause; Pegylated Interferon; Viral HepatitisbusinessBiomarkers
researchProduct

Safety and efficacy of changing to the travoprost/timolol maleate fixed combination (DuoTrav) from prior mono- or adjunctive therapy.

2010

Norbert Pfeiffer1, Maria-Luise Scherzer2, Hubert Maier3, Sonja Schoelzel4, Mark C Jasek5, Jeanette A Stewart6, William C Stewart6 On behalf of the DuoTravMED study group1Johannes Gutenberg-Universität Mainz, Mainz, Germany; 2Regenstauf, Germany; 3Gerolzhofen, Germany; 4Institutes of Molecular Medicine, University of Freiburg, Department of Surgery, Freiburg, Germany; 5Alcon Laboratories, Inc., Fort Worth, TX, USA; 6PRN Pharmaceutical Research Network, LLC, Charleston, SC, USAPurpose: To assess the safety and efficacy of changing to the travoprost/timolol fixed combination (TTFC) from other mono- or adjunctive therapies.Patients and methods: A prospective, open-label, observational …

Timolol maleatesafetyIntraocular pressuremedicine.medical_specialtyprimary open-angle glaucomagenetic structuresbusiness.industrytravoprost/timolol fixed combinationefficacyTimololOcular hypertensionClinical Ophthalmologymedicine.diseaseeye diseasesOphthalmologyOphthalmologymedicineocular hypertensionTravoprostsense organsskin and connective tissue diseasesbusinessmedicine.drugOriginal Researchintraocular pressureClinical ophthalmology (Auckland, N.Z.)
researchProduct

Recombination profiles between Tomato yellow leaf curl virus and Tomato yellow leaf curl Sardinia virus in laboratory and field conditions: evolution…

2012

Tomato yellow leaf curl Sardinia virus and Tomato yellow leaf curl virus have co-existed in Italian tomato crops since 2002 and have reached equilibrium, with plants hosting molecules of both species plus their recombinants being the most frequent case. Recombination events are studied in field samples, as well as in experimental co-infections, when recombinants were detected as early as 45 days following inoculation. In both conditions, recombination breakpoints were essentially absent in regions corresponding to ORFs V2, CP and C4, whereas density was highest in the 3′-terminal portion of ORF C3, next to the region where the two transcription units co-terminate. The vast majority of brea…

Tomato yellow leaf curl Sardinia virusvirusesTYLCVGenomeRecombination TYLCDTYLCSVEvolution MolecularSolanum lycopersicumSpecies SpecificityTranscription (biology)VirologyBotanySense (molecular biology)Tomato yellow leaf curl virusORFSPhylogenyPlant DiseasesGeneticsRecombination GeneticbiologyBase SequenceVirulenceInoculationfungiSettore AGR/12 - Patologia Vegetalefood and beveragesbiology.organism_classificationVirologyrecombinationItalySpainBegomovirusDNA ViralGeminivirusRecombination
researchProduct

Effect of two antihypertensive combinations on metabolic control in type-2 diabetic hypertensive patients with albuminuria: a randomised, double-blin…

2001

The objective of this study was to compare, at equal blood pressure (BP) reduction, the effect of two different combinations on metabolic control and albuminuria in type 2 diabetic hypertensive patients with albuminuria. This was a prospective, randomised, double-blind, parallel, controlled trial carried out in 11 Spanish hospitals. A total of 103 type 2 diabetic patients with stable albuminuria and BP not controlled on monotherapy were randomised of which 93 finished the study. After a 4-week single-blind placebo period, patients were randomised to verapamil SR/trandolapril 180/2 mg (VT) or to enalapril/hydroclorothiazide 20/12.5 mg (EH). Treatment duration was 6 months. The main outcome m…

TrandolaprilMalemedicine.medical_specialtyIndolesUrologychemistry.chemical_compoundHydrochlorothiazideDouble-Blind MethodEnalaprilDiabetes mellitusInternal MedicinemedicineAlbuminuriaHumansEnalaprilProspective StudiesAntihypertensive AgentsAgedProbabilityCreatinineAnalysis of Variancebusiness.industryMiddle Agedmedicine.diseaseBlood pressureHydrochlorothiazideTreatment OutcomechemistryDiabetes Mellitus Type 2VerapamilSpainHypertensionMultivariate AnalysisAlbuminuriaUric acidDrug Therapy CombinationFemalemedicine.symptombusinessmedicine.drugFollow-Up StudiesJournal of human hypertension
researchProduct

Molecular characterization of an inducible p-coumaric acid decarboxylase from Lactobacillus plantarum: gene cloning, transcriptional analysis, overex…

1997

By using degenerate primers designed from the first 19 N-terminal amino acids of Lactobacillus plantarum p-coumaric acid decarboxylase (PDC), a 56-bp fragment was amplified from L. plantarum in PCRs and used as a probe for screening an L. plantarum genomic bank. Of the 2,880 clones in the genomic bank, one was isolated by colony hybridization and contained a 519-bp open reading frame (pdc gene) followed by a putative terminator structure. The pdc gene is expressed on a monocistronic transcriptional unit, which is transcribed from promoter sequences homologous to Lactococcus promoter sequences. No mRNA from pdc and no PDC activity were detected in uninduced cell extracts, indicating that the…

Transcription GeneticCarboxy-LyasesMolecular Sequence Datamacromolecular substancesMolecular cloningmedicine.disease_causePolymerase Chain ReactionApplied Microbiology and BiotechnologyOpen Reading FramesLactococcusGene expressionEscherichia colimedicineGenomic libraryAmino Acid SequenceCloning MolecularPromoter Regions GeneticEscherichia coliGeneGene LibraryRecombination GeneticElectronic Data ProcessingBase SequenceEcologybiologyNucleic acid sequenceChromosome MappingNucleic Acid Hybridizationhemic and immune systemsGene Expression Regulation BacterialBlotting Northernbiology.organism_classificationMolecular biologyRecombinant ProteinsBlotting SouthernLactobacillusRNA BacterialTerminator (genetics)BiochemistryEnzyme InductionElectrophoresis Polyacrylamide GelLactobacillus plantarumResearch ArticleFood ScienceBiotechnologyApplied and Environmental Microbiology
researchProduct